Replies to post #46502 on OncoSec Medical Inc (ONCSQ)

[akhsv777]

I'm also thinking along the same line. Multi-gene construct can be the true game changer- unlimited potential. Hard to even throw in a rough estimate.

We do know the current and projected PD-1 inhabitor market (projected to reach ~$30B by 2022) and % for PD-1 inhibitors non-responders so we can make a rough estimate of ONCS's value.

Can you imagine if Merck can increase the efficacy of keytruda with ONCS science? It means a high competitive advantage and able to cement in the unlimited immuno-oncology space. I am sure they taken notice so they may pull the trigger in any moment as long as ONCS continuously producing similar or better results. Just my honest opinion.